Salvage therapy of refractory and relapsed acute leukemia with high dose mitoxantrone and high dose cytarabine

Pia Raanani; Ofer Shpilberg; Shmuel Gillis; Abraham Avigdor; Izhar Hardan; Miriam Berkowicz; Orit Sofer; Izidore Lossos; Angela Chetrit; Dina Ben-Yehuda; Isaac Ben-Bassat

doi:10.1016/S0145-2126(99)00078-8

Salvage therapy of refractory and relapsed acute leukemia with high dose mitoxantrone and high dose cytarabine

Pia Raanani, Ofer Shpilberg, Shmuel Gillis, Abraham Avigdor, Izhar Hardan, Miriam Berkowicz, Orit Sofer, Izidore Lossos, Angela Chetrit, Dina Ben-Yehuda, Isaac Ben-Bassat

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

We have assessed the outcome of 66 refractory and relapsed acute leukemia patients treated with high dose mitoxantrone and cytarabine. Therapy consisted of a total dose of 40-60 mg/m² mitoxantrone and 3 g/m² of cytarabine daily on 5 consecutive days. A total of 28 patients were treated for primary resistant and 38 patients for early or late relapsed leukemia. A total of 35 patients achieved CR. Four patients died during the induction course. Toxicity was acceptable and comparable to other salvage regimens. The median disease-free and overall survivals were 4 and 6 months, respectively. Although this regimen is effective in achieving remission in refractory leukemia, its duration is short.

Original language	English
Pages (from-to)	695-700
Number of pages	6
Journal	Leukemia Research
Volume	23
Issue number	8
DOIs	https://doi.org/10.1016/S0145-2126(99)00078-8
State	Published - 1 Aug 1999
Externally published	Yes

Keywords

Acute leukemia
HIDAC
Mitoxantrone
Refractory
Relapsed
Salvage

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0145-2126(99)00078-8

Cite this

@article{9d5b3fa6f9a74da7a1917d69fb148d84,

title = "Salvage therapy of refractory and relapsed acute leukemia with high dose mitoxantrone and high dose cytarabine",

abstract = "We have assessed the outcome of 66 refractory and relapsed acute leukemia patients treated with high dose mitoxantrone and cytarabine. Therapy consisted of a total dose of 40-60 mg/m2 mitoxantrone and 3 g/m2 of cytarabine daily on 5 consecutive days. A total of 28 patients were treated for primary resistant and 38 patients for early or late relapsed leukemia. A total of 35 patients achieved CR. Four patients died during the induction course. Toxicity was acceptable and comparable to other salvage regimens. The median disease-free and overall survivals were 4 and 6 months, respectively. Although this regimen is effective in achieving remission in refractory leukemia, its duration is short.",

keywords = "Acute leukemia, HIDAC, Mitoxantrone, Refractory, Relapsed, Salvage",

author = "Pia Raanani and Ofer Shpilberg and Shmuel Gillis and Abraham Avigdor and Izhar Hardan and Miriam Berkowicz and Orit Sofer and Izidore Lossos and Angela Chetrit and Dina Ben-Yehuda and Isaac Ben-Bassat",

year = "1999",

month = aug,

day = "1",

doi = "10.1016/S0145-2126(99)00078-8",

language = "English",

volume = "23",

pages = "695--700",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd.",

number = "8",

}

TY - JOUR

T1 - Salvage therapy of refractory and relapsed acute leukemia with high dose mitoxantrone and high dose cytarabine

AU - Raanani, Pia

AU - Shpilberg, Ofer

AU - Gillis, Shmuel

AU - Avigdor, Abraham

AU - Hardan, Izhar

AU - Berkowicz, Miriam

AU - Sofer, Orit

AU - Lossos, Izidore

AU - Chetrit, Angela

AU - Ben-Yehuda, Dina

AU - Ben-Bassat, Isaac

PY - 1999/8/1

Y1 - 1999/8/1

N2 - We have assessed the outcome of 66 refractory and relapsed acute leukemia patients treated with high dose mitoxantrone and cytarabine. Therapy consisted of a total dose of 40-60 mg/m2 mitoxantrone and 3 g/m2 of cytarabine daily on 5 consecutive days. A total of 28 patients were treated for primary resistant and 38 patients for early or late relapsed leukemia. A total of 35 patients achieved CR. Four patients died during the induction course. Toxicity was acceptable and comparable to other salvage regimens. The median disease-free and overall survivals were 4 and 6 months, respectively. Although this regimen is effective in achieving remission in refractory leukemia, its duration is short.

AB - We have assessed the outcome of 66 refractory and relapsed acute leukemia patients treated with high dose mitoxantrone and cytarabine. Therapy consisted of a total dose of 40-60 mg/m2 mitoxantrone and 3 g/m2 of cytarabine daily on 5 consecutive days. A total of 28 patients were treated for primary resistant and 38 patients for early or late relapsed leukemia. A total of 35 patients achieved CR. Four patients died during the induction course. Toxicity was acceptable and comparable to other salvage regimens. The median disease-free and overall survivals were 4 and 6 months, respectively. Although this regimen is effective in achieving remission in refractory leukemia, its duration is short.

KW - Acute leukemia

KW - HIDAC

KW - Mitoxantrone

KW - Refractory

KW - Relapsed

KW - Salvage

UR - http://www.scopus.com/inward/record.url?scp=0032767878&partnerID=8YFLogxK

U2 - 10.1016/S0145-2126(99)00078-8

DO - 10.1016/S0145-2126(99)00078-8

M3 - Article

AN - SCOPUS:0032767878

SN - 0145-2126

VL - 23

SP - 695

EP - 700

JO - Leukemia Research

JF - Leukemia Research

IS - 8

ER -

Salvage therapy of refractory and relapsed acute leukemia with high dose mitoxantrone and high dose cytarabine

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this